Drug Trial Radar · NCT06132113
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Actual
Start
Jan 22, 2024
Primary completion
Oct 9, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has Part A1, Part A2, and Part B. Part A1 of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. Part A2 of this study is to find out how well people tolerate a low dose of BI 764532 combined with the chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC. Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it. Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour.
Conditions
- Neuroendocrine Neoplasms
Interventions
BI 764532Drug
BI 764532
CarboplatinDrug
Standard of care
EtoposideDrug
Standard of care
CisplatinDrug
Standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: Up to 21 days.
- Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment periodTime frame: Up to 36 months.
- Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment periodTime frame: Up to 36 months.
Locations
21 sites in 8 countries. Site status is shown where the registry gives one.
University of Miami
Miami, Florida
Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
John Theurer Cancer Center
Hackensack, New Jersey
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Hopital Louis Pradel
Bron, France
INS Paoli-Calmettes
Marseille, France
Klinikum der Universität München AÖR
München, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Aichi Cancer Center Hospital
Aichi, Nagoya, Japan
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Sahlgrenska Universitetsjukhuset
Gothenburg, Sweden
Uppsala University Hospital
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.